The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma

The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma

Abstract Background The blood–brain barrier (BBB) severely limits the entry of systemically administered drugs including chemotherapy to the brain. In rodents, regadenoson activation of adenosine A2A receptors causes transient BBB disruption and increased drug concentrations in normal brain. This st...

Full description

Bibliographic Details
Main Authors: Sadhana Jackson, Jon Weingart, Edjah K. Nduom, Thura T. Harfi, Richard T. George, Dorothea McAreavey, Xiaobu Ye, Nicole M. Anders, Cody Peer, William D. Figg, Mark Gilbert, Michelle A. Rudek, Stuart A. Grossman
Format: Article
Language:English
Published: BMC 2018-01-01
Series:Fluids and Barriers of the CNS
Subjects:
Temozolomide
Adenosine A2A agonist
Regadenoson
Microdialysis
Glioblastoma
High grade glioma
Online Access:http://link.springer.com/article/10.1186/s12987-017-0088-8

Internet

http://link.springer.com/article/10.1186/s12987-017-0088-8

Similar Items